These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
740 related articles for article (PubMed ID: 17201732)
1. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. Hong XZ; Li LD; Wu LM Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732 [TBL] [Abstract][Full Text] [Related]
2. Protective effects of the Alisma orientalis extract on the experimental nonalcoholic fatty liver disease. Hong X; Tang H; Wu L; Li L J Pharm Pharmacol; 2006 Oct; 58(10):1391-8. PubMed ID: 17034663 [TBL] [Abstract][Full Text] [Related]
3. Preventive effects of total flavonoids of Litsea coreana leve on hepatic steatosis in rats fed with high fat diet. Wang JQ; Li J; Zou YH; Cheng WM; Lu C; Zhang L; Ge JF; Huang C; Jin Y; Lv XW; Hu CM; Liu LP J Ethnopharmacol; 2009 Jan; 121(1):54-60. PubMed ID: 18977425 [TBL] [Abstract][Full Text] [Related]
4. Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats. Qin R; Zhang J; Li C; Zhang X; Xiong A; Huang F; Yin Z; Li K; Qin W; Chen M; Zhang S; Liang L; Zhang H; Nie H; Ye W Arch Pharm Res; 2012 Jul; 35(7):1241-50. PubMed ID: 22864747 [TBL] [Abstract][Full Text] [Related]
5. [Effect of peroxisome proliferator-activated receptor-alpha agonist on adipokines expression in rats fed with high-fat diet]. Li Y; Huang B; Cheng H; Liang Z; Liu SY Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Dec; 28(6):761-5. PubMed ID: 17260462 [TBL] [Abstract][Full Text] [Related]
6. [Effects of fenofibrate on gene expression of carnitine palmitoyltransferase 1 in liver and skeletal muscle and its influence on insulin sensitivity]. Bai XP; Li HL; Yang WY; Xiao JZ; Wang B; Du RQ; Lou DJ Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):268-70. PubMed ID: 18361841 [TBL] [Abstract][Full Text] [Related]
7. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007 [TBL] [Abstract][Full Text] [Related]
8. [Effects of total glucosides of paeony on enhancing insulin sensitivity and antagonizing nonalcoholic fatty liver in rats]. Zheng LY; Pan JQ; Lv JH Zhongguo Zhong Yao Za Zhi; 2008 Oct; 33(20):2385-90. PubMed ID: 19157135 [TBL] [Abstract][Full Text] [Related]
9. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. Yalniz M; Bahcecioglu IH; Kuzu N; Poyrazoglu OK; Bulmus O; Celebi S; Ustundag B; Ozercan IH; Sahin K J Gastroenterol Hepatol; 2007 Nov; 22(11):2009-14. PubMed ID: 17914984 [TBL] [Abstract][Full Text] [Related]
10. Triterpenoid-rich fraction from Ilex hainanensis Merr. attenuates non-alcoholic fatty liver disease induced by high fat diet in rats. Cui WX; Yang J; Chen XQ; Mao Q; Wei XL; Wen XD; Wang Q Am J Chin Med; 2013; 41(3):487-502. PubMed ID: 23711137 [TBL] [Abstract][Full Text] [Related]
11. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats. Laurent D; Gounarides JS; Gao J; Boettcher BR Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377 [TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate. Forcheron F; Abdallah P; Basset A; del Carmine P; Haffar G; Beylot M Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925 [TBL] [Abstract][Full Text] [Related]
13. Dynamic expression of hepatic thioredoxin mRNA in rats with non-alcoholic fatty liver disease. Duan XY; Zhao HP; Fan JG J Dig Dis; 2010 Apr; 11(2):94-100. PubMed ID: 20402835 [TBL] [Abstract][Full Text] [Related]
14. [Therapy effects of fenofibrate on alcoholic fatty liver and drug-induced fatty liver in rats]. Yan M; Meng FL; Lu RJ; Jia XQ; Zhao XC Zhonghua Gan Zang Bing Za Zhi; 2003 Feb; 11(2):86-9. PubMed ID: 12648401 [TBL] [Abstract][Full Text] [Related]
15. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Cong WN; Tao RY; Tian JY; Liu GT; Ye F Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155 [TBL] [Abstract][Full Text] [Related]
16. Induction of non-alcoholic fatty liver disease and insulin resistance by feeding a high-fat diet in rats: does coenzyme Q monomethyl ether have a modulatory effect? Safwat GM; PisanĂ² S; D'Amore E; Borioni G; Napolitano M; Kamal AA; Ballanti P; Botham KM; Bravo E Nutrition; 2009; 25(11-12):1157-68. PubMed ID: 19592219 [TBL] [Abstract][Full Text] [Related]
17. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348 [TBL] [Abstract][Full Text] [Related]
18. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Baumgardner JN; Shankar K; Hennings L; Badger TM; Ronis MJ Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G27-38. PubMed ID: 17947452 [TBL] [Abstract][Full Text] [Related]